These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20006793)

  • 41. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is lipid management effective for all stages of CKD?
    Ku E; Campese V
    Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Ezetimibe as a treatment for dyslipidaemia in CKD].
    Żebrowski P; Kaszyńska M
    Wiad Lek; 2019; 72(11 cz 2):2210-2213. PubMed ID: 31860838
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HMG-CoA reductase inhibitors in chronic kidney disease.
    Olyaei A; Steffl JL; MacLaughlan J; Trabolsi M; Quadri SP; Abbasi I; Lerma E
    Am J Cardiovasc Drugs; 2013 Dec; 13(6):385-98. PubMed ID: 23975627
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dyslipidemia and the progression of renal disease in chronic renal failure patients.
    Cases A; Coll E
    Kidney Int Suppl; 2005 Dec; (99):S87-93. PubMed ID: 16336584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
    Katsiki N; Mikhailidis DP; Banach M
    Expert Opin Pharmacother; 2019 Nov; 20(16):2007-2017. PubMed ID: 31344332
    [No Abstract]   [Full Text] [Related]  

  • 47. The role of statins in chronic kidney disease.
    Agarwal R; Curley TM
    Am J Med Sci; 2005 Aug; 330(2):69-81. PubMed ID: 16103787
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials.
    Chan DT; Irish AB; Dogra GK; Watts GF
    Atherosclerosis; 2008 Feb; 196(2):823-34. PubMed ID: 17343861
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients.
    Olyaei A; Greer E; Delos Santos R; Rueda J
    Clin J Am Soc Nephrol; 2011 Mar; 6(3):664-78. PubMed ID: 21393488
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Lipid metabolism abnormalities in Chronic Kidney Disease].
    Bianchi S; Baronti A; Cominotto R; Bigazzi R
    G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
    Vijayaraghavan K; Szerlip HM; Ballantyne CM; Bays HE; Philip S; Doyle RT; Juliano RA; Granowitz C
    Postgrad Med; 2019 Aug; 131(6):390-396. PubMed ID: 31306043
    [No Abstract]   [Full Text] [Related]  

  • 53. HMG CoA reductase inhibitors (statins) for dialysis patients.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Nigwekar SU; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2013 Sep; 2013(9):CD004289. PubMed ID: 24022428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia.
    Chung CM; Lin MS; Hsu JT; Hsiao JF; Chang ST; Pan KL; Lin CL; Lin YS
    J Clin Lipidol; 2017; 11(2):422-431.e2. PubMed ID: 28502499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
    Lin YC; Lai TS; Wu HY; Chou YH; Chiang WC; Lin SL; Chen YM; Chu TS; Tu YK
    Clin Pharmacol Ther; 2020 Oct; 108(4):833-843. PubMed ID: 32320058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.
    Bajaj A; Xie D; Cedillo-Couvert E; Charleston J; Chen J; Deo R; Feldman HI; Go AS; He J; Horwitz E; Kallem R; Rahman M; Weir MR; Anderson AH; Rader DJ;
    Am J Kidney Dis; 2019 Jun; 73(6):827-836. PubMed ID: 30686529
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
    McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM
    Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.
    Sanguankeo A; Upala S; Cheungpasitporn W; Ungprasert P; Knight EL
    PLoS One; 2015; 10(7):e0132970. PubMed ID: 26151753
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Statin therapy in renal disease: harmful or protective?
    McCullough PA; Rocher LR
    Curr Atheroscler Rep; 2007 Jan; 9(1):18-24. PubMed ID: 17169242
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis.
    Su X; Zhang L; Lv J; Wang J; Hou W; Xie X; Zhang H
    Am J Kidney Dis; 2016 Jun; 67(6):881-92. PubMed ID: 26905361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.